Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, open-label, single-arm, multicenter study to evaluate the efficacy, safety and tolerability of CDB-2914 [ulipristal] as emergency contraception when taken between 48 hours and 120 hours of unprotected sex

X
Trial Profile

A prospective, open-label, single-arm, multicenter study to evaluate the efficacy, safety and tolerability of CDB-2914 [ulipristal] as emergency contraception when taken between 48 hours and 120 hours of unprotected sex

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ulipristal (Primary)
  • Indications Pregnancy
  • Focus Registrational; Therapeutic Use
  • Sponsors HRA Pharma
  • Most Recent Events

    • 13 Aug 2010 According to a company media release, Watson Pharmaceuticals plans to launch Ella [ulipristal] as an emergency contraceptive in the fourth quater of 2010.
    • 13 Aug 2010 According to an HRA Pharma media release, the US FDA has granted approval for ulipristal as a prescription-only emergency contraceptive, based on results of this and another phase III trial (CTP 700022221).
    • 21 Apr 2008 Status change from recruiting to completed, according to clinicaltrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top